| |
|
|
|
Xtalks, Online
2025-10-27
Psychedelic drug development is advancing quickly, but clinical progress often stalls due to small datasets, regulatory uncertainty and a lack of objective biomarkers.
With over 94% of psychiatric compounds failing to reach the market after entering Phase I, this therapeutic area has the second highest attrition rate in drug development. Neuroimaging offers a potential solution by providing a data-driven foundation for more reliable, reproducible and objective advancement across preclinical and clinical stages.
This webinar is designed for researchers, clinical developers and investors looking to accelerate psychedelic therapy programs with scientifically grounded insights. Discover how advanced neuroimaging techniques, such as PET and fMRI, and other multimodal approaches, are clarifying mechanisms of action, validating biomarkers and guiding precision dosing and patient stratification.
Join the featured speaker to explore:
How neuroimaging is uncovering unique neuroplasticity and connectivity effects linked to therapeutic outcomes
Real-world examples of imaging data informing smarter trial designs and patient selection
Practical strategies for integrating imaging insights into regulatory submissions and clinical decision-making
Register for this webinar to see how neuroimaging can optimize psychedelic drug development, reduce risk, improve study design and help bring safe and effective treatments.
Keywords: Biomarker Validation, Biomarkers, Clinical Research, CNS, CNS Drug Development, CRO, Drug Development, fMRI Psychedelic Research, Multimodal Neuroimaging, Neuroimaging in Psychiatry, PET Imaging Psychedelics, Psychedelic Drug Development, Psychedelic Therapy Research, Therapeutic Areas
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Matthew Wall, PhD, Associate Director of Translational MRI, Perceptive
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2025-10-27
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|